{"id":48011,"date":"2021-06-25T06:09:19","date_gmt":"2021-06-25T06:09:19","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=75603"},"modified":"2021-06-25T06:09:19","modified_gmt":"2021-06-25T06:09:19","slug":"orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease","status":"publish","type":"post","link":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/","title":{"rendered":"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease"},"content":{"rendered":"

Orphalan Announces Positive Top<\/strong> Line Data with <\/strong>Trientine<\/strong> Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease\u00a0<\/strong>\u00a0<\/strong>
\n\u00a0<\/strong>
\nJUNE 2<\/strong>5<\/strong>, 2021 – ORPHAN DISEASES\u00a0<\/strong><\/p>\n

\u2014\u00a0<\/em>CHELATE trial confirmed <\/em>t<\/em>rientine<\/em> tetrahydrochloride <\/em>was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin <\/em>Copper <\/em>(NCC<\/em>)<\/em> levels <\/em>as a <\/em>maintenance <\/em>therapy for <\/em>patients with Wilson<\/em>\u2019s<\/em> Disease<\/em>,<\/em> following six months of treatment<\/em>.<\/em><\/p>\n

\u2014\u00a0<\/em>T<\/em>rientine<\/em> tetrahydrochloride was well tolerated and during treatment<\/em>,<\/em> more patients achieved the pre-specified composite endpoint of NCC and 24<\/em>–<\/em>hour Urinary Copper Excretion (UCE) within therapeutic target ranges, compared to patients treated with d-Penicillamine, 50% versus 24%.\u00a0\u00a0<\/em><\/p>\n

\u2014\u00a0<\/em>Data from the trial to be presented today during an oral presentation at <\/em>EASL\u2019s <\/em>The International Liver Congress\u2122 2021.\u00a0<\/em><\/p>\n

Paris, France.<\/strong> June 25, 2021 (GLOBE NEWSWIRE) Orphalan SA is a company that identifies, develops and delivers innovative treatments to patients with rare diseases. Orphalan today announced positive top line results from a phase 3 head-to-head trial comparing d-Penicillamine with trientine tetrahydrochloride in Wilson\u2019s Disease (WD). The phase 3 trial has been completed through an IND program for FDA submission. Wilson\u2019s Disease is a rare inherited disorder of copper transport primarily affecting the liver and brain. Untreated, this is a fatal disease.<\/p>\n

The CHELATE trial is the first prospective randomised trial comparing d-Penicillamine with trientine tetrahydrochloride. D- Penicillamine has been the only approved first line treatment for the last 70 years. Trientine tetrahydrochloride if approved has the potential to be used as maintenance therapy in patients with Wilson\u2019s Disease.<\/p>\n

The CHELATE trial met its primary efficacy endpoint by demonstrating that trientine tetrahydrochloride was non-inferior to d-Penicillamine as measured by copper speciation evaluation of non-ceruloplasmin copper (NCC). This novel analytical method was developed by Orphalan through consultation with the FDA. The pre-specified composite endpoint of non-ceruloplasmin copper (NCC) and 24-hour urinary copper excretion (UCE), was achieved by 50% of patients treated with trientine tetrahydrochloride\u00a0versus 24% of patients treated with d-Penicillamine.<\/p>\n

Five serious adverse events (SAEs) were observed in the 27 patients treated with d-Penicillamine, while no SAEs were observed in the 26 patients randomised to trientine tetrahydrochloride. Treatment emergent adverse events (TEAEs) temporally related to the study treatments reported in the study were comparable in both groups and were graded as either mild or moderate and transitory in nature.<\/p>\n

The data arising from this study will be presented at EASL\u2019s International Liver Congress today at 8.45 CEST and will be submitted for publication. Analysis of the 48-week data from the CHELATE Phase 3 investigational study is ongoing and will be presented at a future scientific forum.<\/p>\n

\u201cWith a chronic disorder like Wilson\u2019s Disease, interrupting or stopping treatment for any reason can provoke the return of disease activity, sometimes with severe consequences. Physicians and patients should work together to choose a medication that provides the right balance of efficacy, safety and tolerability to help manage patients\u2019 Wilson\u2019s Disease and meet their treatment goals,\u201d\u00a0said <\/strong>Dr.<\/strong>\u00a0Michael <\/strong>Schilsky<\/strong>\u00a0, Principal Investigator and <\/strong>Professor of Medicine and Director of the <\/strong>Center<\/strong> for Excellence for Wilson <\/strong>D<\/strong>isease at Yale University<\/strong>.<\/strong>\u00a0\u201cThese top-line results suggest that trientine tetrahydrochloride offers a differentiated tolerability profile and represents a safe and effective alternative to d-Penicillamine as a maintenance therapy for patients with Wilson\u2019s Disease.\u201d<\/p>\n

\u201cDespite its poor safety profile, d-Penicillamine is the only approved first line therapy in\u00a0Wilson\u2019s\u00a0Disease. The CHELATE study showed that patients on d-Penicillamine can be safely switched to trientine tetrahydrochloride, without compromising efficacy. Our commitment to this study is in line with our strategy to provide robust clinical data to physicians to enable them to make evidence-based treatment decisions.\u201d\u00a0said <\/strong>Dr<\/strong>.<\/strong> Naseem Amin, Chief Executive Officer at Orphalan.<\/strong>\u00a0He added: \u201cThe clinical evidence from this trial and the use of the novel assay for NCC developed by Orphalan have the potential to make a meaningful difference to the patient\u2019s life and the physician\u2019s ability to monitor their disease.\u201d<\/p>\n

Notes to Editors<\/strong><\/p>\n

About<\/strong> the <\/strong>CHELATE\u00a0<\/strong>Study<\/strong><\/p>\n

CHELATE is a Phase 3, multicentre, randomised, open label, active-controlled, non-inferiority study conducted in 9 countries at 15 centres\u00a0designed to evaluate efficacy and safety of trientine tetrahydrochloride compared to d-Penicillamine in patients with stable Wilson\u2019s Disease.\u00a0Fifty-three adult Wilson\u2019s Disease patients with clinically stable disease for over one year and who met specific inclusion criteria, including laboratory measures of serum non-ceruloplasmin copper (NCC), 24-hour urinary copper excretion (UCE) and liver function tests, were followed for a baseline period for 12 weeks before being randomised 1:1 to either trientine tetrahydrochloride or d-Penicillamine twice daily. The study\u2019s primary endpoint was serum NCC as measured using Orphalan\u2019s proprietary method using copper speciation at 24-weeks post-randomisation. A secondary composite efficacy endpoint was NCC and 24-hour UCE.<\/p>\n

Additional secondary endpoints included were: clinical Global Impression of Change (CGIC) score; serum copper and ceruloplasmin levels; the unified Wilson\u2019s Disease Rating Scale (UWDRS); modified Nazer score; cognitive assessments and standard safety assessments. In addition, an independent adjudication committee blinded to the allocated treatment, and study centres assessed key efficacy and safety parameters to determine clinical stability of the patient.\u00a0<\/strong><\/p>\n

About\u00a0<\/strong>Trientine<\/strong> Tetrahydrochloride<\/strong>
\nTrientine tetrahydrochloride is an investigational, novel oral trientine formulation with Orphan Drug Designation under development through a 505(b)(2) pathway for the treatment of Wilson\u2019s Disease maintenance patients.\u00a0The trientine tetrahydrochloride NDA is planned to be submitted mid-year 2021. If approved by the FDA, Orphalan intends to market trientine tetrahydrochloride itself in the US.<\/p>\n

About the\u00a0<\/strong>Trientine<\/strong> Tetrahydrochloride<\/strong>\u00a0<\/strong>Clinical Development Program<\/strong>
\nThe key components of the clinical development program of trientine tetrahydrochloride include the CHELATE trial, a Phase 3, open-label, six-month safety and efficacy study in maintenance Wilson\u2019s Disease patients, along with pharmacokinetic bridging studies comparing trientine tetrahydrochloride to two formulations of trientine dihydrochloride, Triumph I and Triumph 2. The CHELATE clinical development program also includes the CHELATE extension phase, assessing the safety, efficacy and tolerability of trientine tetrahydrochloride and d-Penicillamine over a period of 1 year.\u00a0<\/strong><\/p>\n

About <\/strong>Cuprior<\/strong>\u2122<\/strong>
\nCuprior\u2122 is a form of trientine tetrahydrochloride which is approved in the EU\u00a0for patients intolerant to d-Penicillamine.\u00a0Of the estimated 5,000 diagnosed Wilson\u2019s Disease patients in the EU, we estimate 25% are considered intolerant.<\/p>\n

Cuprior\u2122 is contraindicated in patients hypersensitive to trientine.<\/p>\n

Cuprior\u2122\u00a0is a registered and unregistered trademark of\u00a0Orphalan.<\/p>\n

For\u00a0important safety information and full prescribing information, including patient information\u00a0for Cuprior\u2122 please visit \u00a0https:\/\/www.cuprior.com<\/a><\/p>\n

Trientine tetrahydrochloride is under investigation and not approved for use in any indication in the United States.<\/p>\n

About Orphalan<\/strong>
\nAt Orphalan, our mission is clear: we are pioneers in orphan diseases. Orphalan is a company that identifies, develops and delivers innovative treatments to patients with rare diseases. Orphalan was founded in 2011 and\u00a0has launched Cuprior\u2122 across Europe with its own commercial organisation.<\/p>\n

\nContact for <\/strong>Orphalan<\/strong>: <\/strong>
\nTel : +33 (0)1 42 49 82 64
\ninfo@orphalan.health<\/a><\/p>\n

Contact For Media:
\nConsilium Strategic Communications:\u00a0<\/strong>
\nMary-Jane Elliott, Allison Connolly
\nTel: +44 (0) 203 709 5700
\norphalan@consilium-comms.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease\u00a0\u00a0 \u00a0 JUNE 25, 2021 \u2013 ORPHAN DISEASES\u00a0 \u2014\u00a0CHELATE trial confirmed trientine tetrahydrochloride was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin Copper (NCC) levels as a maintenance therapy for patients with Wilson\u2019s Disease, following six months of treatment. [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"yoast_head":"\nOrphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease - Malaysian Tribune<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease - Malaysian Tribune\" \/>\n<meta property=\"og:description\" content=\"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease\u00a0\u00a0 \u00a0 JUNE 25, 2021 \u2013 ORPHAN DISEASES\u00a0 \u2014\u00a0CHELATE trial confirmed trientine tetrahydrochloride was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin Copper (NCC) levels as a maintenance therapy for patients with Wilson\u2019s Disease, following six months of treatment. [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Malaysian Tribune\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-25T06:09:19+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/malaysiantribune.com\/#\/schema\/person\/e66cebd3ec3b4c4c7e2efc560786d3f0\"},\"headline\":\"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease\",\"datePublished\":\"2021-06-25T06:09:19+00:00\",\"dateModified\":\"2021-06-25T06:09:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/\"},\"wordCount\":1130,\"publisher\":{\"@id\":\"https:\/\/malaysiantribune.com\/#organization\"},\"articleSection\":[\"PRESS RELEASES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/\",\"url\":\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/\",\"name\":\"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease - Malaysian Tribune\",\"isPartOf\":{\"@id\":\"https:\/\/malaysiantribune.com\/#website\"},\"datePublished\":\"2021-06-25T06:09:19+00:00\",\"dateModified\":\"2021-06-25T06:09:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/malaysiantribune.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/malaysiantribune.com\/#website\",\"url\":\"https:\/\/malaysiantribune.com\/\",\"name\":\"Malaysian Tribune\",\"description\":\"Reach for the Malaysian Tribune\",\"publisher\":{\"@id\":\"https:\/\/malaysiantribune.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/malaysiantribune.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/malaysiantribune.com\/#organization\",\"name\":\"Malaysian Tribune\",\"url\":\"https:\/\/malaysiantribune.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/malaysiantribune.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/malaysiantribune.com\/wp-content\/uploads\/2023\/05\/Malaysian-Tribune-Logo-e1700216043543.png\",\"contentUrl\":\"https:\/\/malaysiantribune.com\/wp-content\/uploads\/2023\/05\/Malaysian-Tribune-Logo-e1700216043543.png\",\"width\":335,\"height\":80,\"caption\":\"Malaysian Tribune\"},\"image\":{\"@id\":\"https:\/\/malaysiantribune.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/malaysiantribune.com\/#\/schema\/person\/e66cebd3ec3b4c4c7e2efc560786d3f0\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/malaysiantribune.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/malaysiantribune.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease - Malaysian Tribune","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/","og_locale":"en_US","og_type":"article","og_title":"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease - Malaysian Tribune","og_description":"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease\u00a0\u00a0 \u00a0 JUNE 25, 2021 \u2013 ORPHAN DISEASES\u00a0 \u2014\u00a0CHELATE trial confirmed trientine tetrahydrochloride was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin Copper (NCC) levels as a maintenance therapy for patients with Wilson\u2019s Disease, following six months of treatment. [\u2026]","og_url":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/","og_site_name":"Malaysian Tribune","article_published_time":"2021-06-25T06:09:19+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/#article","isPartOf":{"@id":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/"},"author":{"name":"admin","@id":"https:\/\/malaysiantribune.com\/#\/schema\/person\/e66cebd3ec3b4c4c7e2efc560786d3f0"},"headline":"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease","datePublished":"2021-06-25T06:09:19+00:00","dateModified":"2021-06-25T06:09:19+00:00","mainEntityOfPage":{"@id":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/"},"wordCount":1130,"publisher":{"@id":"https:\/\/malaysiantribune.com\/#organization"},"articleSection":["PRESS RELEASES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/","url":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/","name":"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease - Malaysian Tribune","isPartOf":{"@id":"https:\/\/malaysiantribune.com\/#website"},"datePublished":"2021-06-25T06:09:19+00:00","dateModified":"2021-06-25T06:09:19+00:00","breadcrumb":{"@id":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/malaysiantribune.com\/orphalan-announces-positive-top-line-data-with-trientine-tetrahydrochloride-for-maintenance-patients-with-wilsons-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/malaysiantribune.com\/"},{"@type":"ListItem","position":2,"name":"Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/malaysiantribune.com\/#website","url":"https:\/\/malaysiantribune.com\/","name":"Malaysian Tribune","description":"Reach for the Malaysian Tribune","publisher":{"@id":"https:\/\/malaysiantribune.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/malaysiantribune.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/malaysiantribune.com\/#organization","name":"Malaysian Tribune","url":"https:\/\/malaysiantribune.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/malaysiantribune.com\/#\/schema\/logo\/image\/","url":"https:\/\/malaysiantribune.com\/wp-content\/uploads\/2023\/05\/Malaysian-Tribune-Logo-e1700216043543.png","contentUrl":"https:\/\/malaysiantribune.com\/wp-content\/uploads\/2023\/05\/Malaysian-Tribune-Logo-e1700216043543.png","width":335,"height":80,"caption":"Malaysian Tribune"},"image":{"@id":"https:\/\/malaysiantribune.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/malaysiantribune.com\/#\/schema\/person\/e66cebd3ec3b4c4c7e2efc560786d3f0","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/malaysiantribune.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/malaysiantribune.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/malaysiantribune.com\/wp-json\/wp\/v2\/posts\/48011"}],"collection":[{"href":"https:\/\/malaysiantribune.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/malaysiantribune.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/malaysiantribune.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/malaysiantribune.com\/wp-json\/wp\/v2\/comments?post=48011"}],"version-history":[{"count":0,"href":"https:\/\/malaysiantribune.com\/wp-json\/wp\/v2\/posts\/48011\/revisions"}],"wp:attachment":[{"href":"https:\/\/malaysiantribune.com\/wp-json\/wp\/v2\/media?parent=48011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/malaysiantribune.com\/wp-json\/wp\/v2\/categories?post=48011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/malaysiantribune.com\/wp-json\/wp\/v2\/tags?post=48011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}